about
Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretionA positive association between homeostasis model assessment of insulin resistance score and the Trp64Arg polymorphism of the β3-Adrenergic receptor gene in schizophrenia patients in Taiwan.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review.Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study).Physical Health and Dual Diagnosis.Metabolic monitoring for patients treated with antipsychotic medications.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.The physical health of the seriously mentally ill: an overview of the literature.Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
P2860
Q28252428-BE51256A-AD71-4FC2-8990-FF354630C408Q34318126-2C448EC9-CD58-4736-8732-E5EB4C040CDFQ34623350-04E3AF46-29D4-4EA9-97FC-A74D6AB439B6Q34996871-DABDCC51-CE4D-4783-BC17-EA8F8E40D9E7Q35290463-9DE526DC-7926-4922-A9C8-73897373215DQ35460642-FDE66B66-0FE3-4149-8647-FAA57FF2F773Q36009165-3BB22814-33BE-4676-B9E5-7A439093847CQ36577861-037CE2E8-793C-41BB-97B9-410F484354DFQ37160453-6C17E17F-5C21-46A3-80E1-494E603D6C64Q37272996-0DABCD0D-573E-42F1-A7F5-C15EB27F3068Q37954427-1921055E-195F-4C50-8FE3-D48EEF5480C0Q38274901-09010B2D-E14B-453C-82C0-E297ACF0FB52Q38826676-434C5A71-78CC-4F6F-9F2E-700E06902AA8Q38981510-CD2667ED-8959-4440-A3C7-A5BDA0DEE3F7Q39404106-D7ECC825-3197-498F-8E3A-938F1B954838Q50737699-7BA09932-4D4C-4D23-AD2C-A936539D3EB6
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Association between antipsychotic drugs and diabetes.
@ast
Association between antipsychotic drugs and diabetes.
@en
type
label
Association between antipsychotic drugs and diabetes.
@ast
Association between antipsychotic drugs and diabetes.
@en
prefLabel
Association between antipsychotic drugs and diabetes.
@ast
Association between antipsychotic drugs and diabetes.
@en
P2860
P1476
Association between antipsychotic drugs and diabetes.
@en
P2093
Richard I G Holt
Robert C Peveler
P2860
P304
P356
10.1111/J.1463-1326.2005.00495.X
P577
2006-03-01T00:00:00Z